BRPI0719865A2 - molécula de ácido nucleico, proteína de fusão purificada, vetor, célula hospedeira, processo para expressar uma proteína de fusão, e, método para tratar um paciente sofrendo de ou predisposto a um câncer - Google Patents

molécula de ácido nucleico, proteína de fusão purificada, vetor, célula hospedeira, processo para expressar uma proteína de fusão, e, método para tratar um paciente sofrendo de ou predisposto a um câncer

Info

Publication number
BRPI0719865A2
BRPI0719865A2 BRPI0719865A BRPI0719865A BRPI0719865A2 BR PI0719865 A2 BRPI0719865 A2 BR PI0719865A2 BR PI0719865 A BRPI0719865 A BR PI0719865A BR PI0719865 A BRPI0719865 A BR PI0719865A BR PI0719865 A2 BRPI0719865 A2 BR PI0719865A2
Authority
BR
Brazil
Prior art keywords
tert
fusion protein
fusion proteins
vector
cancer
Prior art date
Application number
BRPI0719865A
Other languages
English (en)
Inventor
Carmela Mennuni
Elisa Scarselli
Gennaro Ciliberto
Nicola La Monica
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Publication of BRPI0719865A2 publication Critical patent/BRPI0719865A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0719865A 2006-10-12 2007-10-09 molécula de ácido nucleico, proteína de fusão purificada, vetor, célula hospedeira, processo para expressar uma proteína de fusão, e, método para tratar um paciente sofrendo de ou predisposto a um câncer BRPI0719865A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85118306P 2006-10-12 2006-10-12
PCT/EP2007/060713 WO2008043760A1 (en) 2006-10-12 2007-10-09 Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0719865A2 true BRPI0719865A2 (pt) 2016-03-15

Family

ID=38858912

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0719865A BRPI0719865A2 (pt) 2006-10-12 2007-10-09 molécula de ácido nucleico, proteína de fusão purificada, vetor, célula hospedeira, processo para expressar uma proteína de fusão, e, método para tratar um paciente sofrendo de ou predisposto a um câncer

Country Status (16)

Country Link
US (1) US8017387B2 (pt)
EP (1) EP2076531B1 (pt)
JP (1) JP2010505433A (pt)
KR (1) KR20090079938A (pt)
CN (1) CN101522706B (pt)
AT (1) ATE534661T1 (pt)
AU (1) AU2007306368B2 (pt)
BR (1) BRPI0719865A2 (pt)
CA (1) CA2664168A1 (pt)
ES (1) ES2376010T3 (pt)
IL (1) IL198012A0 (pt)
MX (1) MX2009003873A (pt)
NO (1) NO20091840L (pt)
NZ (1) NZ576134A (pt)
RU (1) RU2473691C2 (pt)
WO (1) WO2008043760A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008014521A2 (en) * 2006-07-28 2008-01-31 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
EP2324057B1 (en) * 2008-08-12 2018-03-21 MSD Italia S.r.l. Minigene comprising htpa signal peptide, t-cell epitopes, e. coli ltb and furin sensitive linkers
EP2639299A1 (en) 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
CN102942618B (zh) * 2012-11-14 2014-05-21 中国人民解放军军事医学科学院生物工程研究所 具有肿瘤细胞杀伤活性的端粒蛋白多肽片段及其应用
MX369709B (es) * 2013-03-15 2019-11-19 Univ Pennsylvania Vacunación mejorada contra tirosinasa.
EP3524263A1 (en) 2013-03-28 2019-08-14 Invectys A cancer vaccine for dogs
AU2014242915B2 (en) 2013-03-28 2018-08-09 Invectys A cancer vaccine for cats
KR102224965B1 (ko) * 2013-07-12 2021-03-09 주식회사 젬백스앤카엘 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트
CA2927539A1 (en) 2013-10-28 2015-05-07 Invectys Gene electrotransfer into skin cells
PT3062824T (pt) * 2013-10-28 2020-02-21 Invectys Vacina de adn de codificação da telomerase
US10034922B2 (en) * 2013-11-22 2018-07-31 Gemvax & Kael Co., Ltd. Peptide having angiogenesis inhibitory activity and composition containing same
US10370723B2 (en) 2014-07-17 2019-08-06 Blueprint Medicines Corporation TERT fusions
US12098387B2 (en) 2015-10-19 2024-09-24 University Of Maryland, Baltimore Methods for generating engineered human primary blood dendritic cell lines
KR20200109395A (ko) * 2016-01-19 2020-09-22 화이자 인코포레이티드 암 백신
CA3013718C (en) * 2016-02-05 2023-09-26 Jian Yan Cancer vaccines and methods of treatment using the same
WO2018064588A2 (en) * 2016-09-30 2018-04-05 Weiner, David Tert immunogenic compositions and methods of treatment using the same
WO2018206512A1 (en) 2017-05-09 2018-11-15 Invectys Recombinant measles vaccine expressing htert
CA3069363A1 (en) * 2017-07-11 2019-01-17 Pfizer Inc. Immunogenic compositions comprising cea muc1 and tert
CA3122259A1 (en) * 2018-12-05 2020-06-11 Linearx, Inc. Amplicon expression vector vaccines
EP4333887A4 (en) * 2021-05-05 2025-05-21 Inovio Pharmaceuticals, Inc. Vaccines against coronavirus and methods of use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340372C (en) 1984-07-09 1999-02-02 John D. Clements Production of e. coli lt-b enterotoxin subunit
EP0372928A3 (en) 1988-12-07 1990-06-27 University Of Leicester Heat-labile toxin b subunit fusion proteins
US6413523B1 (en) * 1989-06-02 2002-07-02 The United States Of America As Represented By The Secretary Of The Navy Pharmaceutical composition of escherichia coli heat-labile enterotoxin adjuvant and methods of use
US5241053A (en) * 1990-09-05 1993-08-31 Takeda Chemical Industries, Ltd. Fused proteins comprising glycoprotein gD of HSV-1 and LTB
US6475789B1 (en) 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
EP0954585B1 (en) 1996-10-01 2009-11-25 Geron Corporation Human telomerase reverse transcriptase promoter
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US7585622B1 (en) * 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6093809A (en) 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US7390891B1 (en) * 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
WO1998037181A2 (en) 1997-02-20 1998-08-27 Whitehead Institute For Biomedical Research Telomerase catalytic subunit gene and encoded protein
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US7622549B2 (en) * 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
JP2002508662A (ja) 1997-06-20 2002-03-19 バイエル・アクチエンゲゼルシヤフト ヒトテロメラーゼの触媒サブユニット並びにその診断的及び治療的使用
EP0919243A1 (en) 1997-11-25 1999-06-02 Duphar International Research B.V Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
CN1582337B (zh) 2001-10-11 2011-12-14 默沙东公司 丙型肝炎病毒疫苗
CA2490863A1 (en) * 2002-06-27 2004-01-08 Geron Corporation Cancer vaccine containing cross-species epitopes of telomerase reverse transcriptase
CA2555013C (en) * 2004-02-11 2013-10-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Carcinoembryonic antigen fusions and uses thereof
DE102004035227A1 (de) * 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
WO2006011151A2 (en) 2004-07-28 2006-02-02 Gavish - Galilee Bio Applications Ltd. Vaccine comprising recombinant ct or lt toxin
KR20080018201A (ko) 2005-05-19 2008-02-27 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｅ．ｃｏｌｉ 열 독소의 ｂ­서브유닛 및 항원 및애주번트를 포함하는 백신 조성물
CN1757736A (zh) * 2005-07-26 2006-04-12 浙江大学 一种融合基因载体的构建表达及应用

Also Published As

Publication number Publication date
CA2664168A1 (en) 2008-04-17
AU2007306368A1 (en) 2008-04-17
RU2473691C2 (ru) 2013-01-27
KR20090079938A (ko) 2009-07-22
JP2010505433A (ja) 2010-02-25
EP2076531B1 (en) 2011-11-23
IL198012A0 (en) 2011-08-01
US20080090778A1 (en) 2008-04-17
WO2008043760A1 (en) 2008-04-17
ATE534661T1 (de) 2011-12-15
ES2376010T3 (es) 2012-03-08
NO20091840L (no) 2009-07-10
CN101522706A (zh) 2009-09-02
MX2009003873A (es) 2009-04-22
RU2009117325A (ru) 2010-11-20
AU2007306368B2 (en) 2012-05-03
CN101522706B (zh) 2013-09-04
EP2076531A1 (en) 2009-07-08
NZ576134A (en) 2011-09-30
US8017387B2 (en) 2011-09-13

Similar Documents

Publication Publication Date Title
BRPI0719865A2 (pt) molécula de ácido nucleico, proteína de fusão purificada, vetor, célula hospedeira, processo para expressar uma proteína de fusão, e, método para tratar um paciente sofrendo de ou predisposto a um câncer
BRPI0507579A (pt) molécula de ácido nucleico, vetor, célula hospedeira, processo para expressar uma proteìna de fusão cea em uma célula hospedeira recombinante, proteìna de fusão cea purificada, método de prevenção ou tratamento de cáncer, plasmìdeo de vacina, e, método de tratamento de um mamìfero sofrendo de ou predisposto a um cáncer associados com cea
EA200700849A1 (ru) Первичная/бустерная противомалярийная вакцина
BRPI0407233A (pt) Anticorpo neutralizante, molécula de anticorpo, anticorpo enxertado em cdr, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção da molécula de anticorpo, e, composição farmacêutica
Elliott et al. DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections
WO2006089230A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
BRPI1008692B8 (pt) anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
WO2005110338A3 (de) Identifizierung von oberflächen-assoziierten antigenen für die tumordiagnose und -therapie
DE60044665D1 (de) Her2/neu fusionsproteine
BR112012004823A8 (pt) Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica
BRPI0614761A2 (pt) proteìnas de fusão de albumina
BR0307837A (pt) Anticorpos anti-abeta e seu uso
BR112012003064B8 (pt) anticorpo ou fragmento de ligação de antígeno do mesmo, combinação que os compreende, método de detecção de infecção por rsv, moléculas de ácido nucléico, e método de produção de um anticorpo ou fragmento de ligação de antígeno do mesmo
BRPI0717768B8 (pt) anticorpo, epítopo, sequência de dna isolada, vetor de clonagem ou expressão, processo para a produção do anticorpo, composição farmacêutica, e, uso de um anticorpo
BRPI0619595B8 (pt) anticorpo neutralizante, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção de um anticorpo, composição farmacêutica, e, uso de um anticorpo neutralizante humanizado
MX2024004293A (es) Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika.
WO2005120565A8 (en) Sars vaccines and methods to produce highly potent antibodies
BRPI0509079A (pt) molécula de ácido nucléico, vetor, célula hospedeira, partìculas tipo vìrus, método para produzir vlps, vacina, composições farmacêuticas, e, métodos para evitar infecção por hpv e para induzir uma resposta imune em um animal
Duan et al. A novel disulfide-stabilized single-chain variable antibody fragment against rabies virus G protein with enhanced in vivo neutralizing potency
WO2008118487A3 (en) Compositions and methods for incresing immunogenicity of glycoprotein vaccines
ATE470673T1 (de) Impfstoffe mit lawsoniaintrazellularis- untereinheit
BRPI0511793A (pt) proteìnas quiméricas isoladas de lumazina sintase modificada
ATE417106T1 (de) Chlamydia antigene und deren korrespondierende dna fragmente und verwendungen davon
JP2020501521A5 (pt)
Patel et al. Escherichia coli-based production of a tumor idiotype antibody fragment–tetanus toxin fragment C fusion protein vaccine for B cell lymphoma

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.